Addressing translational challenges in B-cell-depleting therapy development with preclinical humanized mouse models

12 min read
November 20, 2026

B-cell depletion has become a cornerstone therapeutic strategy across oncology, autoimmunity, and transplantation. The clinical success of anti-CD20 antibodies such as rituximab, ocrelizumab, ofatumumab, and obinutuzumab has firmly established B cells as key players in the development and propagation of disease, through their roles in antibody production, antigen presentation, cytokine secretion, and organization of adaptive immune responses (Lee et al., 2021; Abeles et al., 2023). Beyond hematologic malignancies, B-cell-targeted therapies have transformed the management of multiple sclerosis, rheumatoid arthritis, pemphigus vulgaris, and other antibody-mediated disorders, while newer approaches including CAR-T cells and bispecific antibodies are expanding the therapeutic landscape (Lee et al., 2021; Sun et al., 2022).

Challenges in the development of B-cell-depleting therapies

Despite these advances, developing effective B-cell-depleting therapies remains challenging. One major limitation is that depletion of circulating B cells does not necessarily eliminate pathogenic immune populations residing in tissues or long-lived plasma cells, which generally lack CD20 expression, or other B cell markers such as CD19, and can continue producing disease-driving antibodies (Levesque and St. Clair, 2008; Lee et al., 2021). Consequently, clinical responses can be incomplete or transient, particularly in complex autoimmune diseases where multiple immune pathways contribute to pathology (Lee et al., 2021).

Additional challenges arise from the diversity of mechanisms through which therapeutic antibodies mediate B-cell elimination. Antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct cell death can all contribute to efficacy, but their relative importance varies according to antibody design, target antigen density, tissue localization, and the patient's immune status (Kessel et al., 2008; Tedder et al., 2006). Resistance mechanisms, including inadequate effector-cell recruitment, tumor-intrinsic escape pathways, complement regulatory proteins, and immunosuppressive microenvironments, can further reduce treatment efficacy (Di Gaetano et al., 2003; Lykken et al., 2016).

Safety represents an equally important challenge in the development of B-cell-depleting therapies. Sustained depletion of normal B cells can impair humoral immunity, leading to hypogammaglobulinemia and an increased susceptibility to infections, particularly following prolonged or repeated treatment. Anti-CD20-mediated immunosuppression can also enable reactivation of latent infections, notably hepatitis B virus, highlighting the need to balance the depth and duration of B-cell depletion with preservation of protective immunity. These considerations become even more complex with emerging B-cell-targeted modalities. CD19-directed CAR-T cells can induce prolonged B-cell aplasia and hypogammaglobulinemia, together with cytokine release syndrome (CRS), neurotoxicity, and infectious complications. Similarly, T-cell-engaging bispecific antibodies are associated with CRS and, less frequently, immune effector cell-associated neurotoxicity syndrome (ICANS), while cytopenias and hypogammaglobulinemia can further increase infection risk.

These translational hurdles highlight the critical importance of robust preclinical models capable of reproducing human B-cell biology and antibody effector functions. However, currently available mouse models each present important limitations. Wild-type mice treated with murine B-cell targeting antibodies are valuable for investigating depletion mechanisms in immunocompetent settings, but they cannot directly evaluate human therapeutic antibodies and do not reproduce human Fcγ receptor interactions (Uchida et al., 2004; Tedder et al., 2006, Van Damme et al., 2026). For example, humanized CD20 transgenic mice permit testing of clinically relevant anti-human CD20 therapies, yet antibody activity remains influenced by murine Fcγ receptors and complement systems, which differ substantially from those in humans (Hu et al., 2007; Torres et al., 2022, Van Damme et al., 2026). Humanized immune system models improve translational relevance by supporting human immune-cell engraftment, but variability in immune reconstitution, incomplete maturation of certain immune compartments, and donor-dependent heterogeneity remain significant challenges (Semple et al., 2019; Chupp et al., 2024).

Next-generation humanized models for B-cell depletion studies

The need for more predictive models has driven the development of next-generation humanized platforms such as the genO-BRGSF-HIS mouse (Li et al., 2016, Lopez-Lastra et al., 2017). Built on the highly immunodeficient BRGSF background and reconstituted with human hematopoietic stem cells, this model supports robust development of human lymphoid and myeloid compartments, enabling evaluation of therapeutic antibodies within a functional human immune environment (Martin et al., 2024, Martin et al., 2025 ; Majocchi et al., 2025). Importantly, different human B-cell subsets develop in genO-BRGSF-HIS mice, together with circulating human immunoglobulin isotypes indicative of B-cell class switching. The B-cell compartment also expresses clinically relevant differentiation antigens beyond CD20, including CD19, CD38 and BCMA; notably, BCMA expression on CD19⁺ cells is comparable to that observed in human PBMCs. This broad target repertoire expands the model's applicability to emerging B-cell and plasma-cell-directed therapies. Indeed, pharmacological validation has demonstrated B-cell depletion following treatment with the BCMA×CD3 T-cell engager teclistamab, the CD19×CD3 engager blinatumomab, and combined CD20/CD19 targeting with rituximab and inebilizumab, supporting the use of genO-BRGSF-HIS for assessing therapies with distinct targets and mechanisms of action. Together, these features make the genO-BRGSF-HIS model particularly valuable for characterizing efficacy, safety and mode of action of novel B-cell-targeted therapeutics.

An important advance in the preclinical evaluation of next-generation B-cell-targeted therapies was demonstrated by Luca Perico and colleagues, who developed a novel bispecific autoantigen-T-cell engager (BiAATE) designed to selectively eliminate autoreactive B cells while sparing the broader B-cell compartment (Perico et al., 2024). Unlike conventional anti-CD20 therapies, which deplete most CD20-expressing B cells irrespective of antigen specificity, the BiAATE approach redirects T cells against disease-relevant autoreactive B cells through simultaneous binding of human CD3 and a disease-specific autoantigen. Beyond the BiAATE proof-of-concept, the study demonstrated the broader translational value of the genO-panhCD3 mouse model for testing emerging B-cell-depleting modalities that depend on human CD3 engagement, including CD19×CD3 and CD20×CD3 bispecific antibodies. As these therapies rely on the formation of functional T-cell/B-cell synapses and accurate human CD3 signaling, conventional mouse models are often insufficient. The genO-panhCD3 model therefore represents a valuable tool for assessing efficacy, pharmacodynamic responses, and mechanism of action of T-cell-engaging B-cell-depleting therapies before clinical development (Perico et al., 2024).

Another important consideration for B-cell-depleting antibodies is the role played by Fcγ receptors in mediating cytotoxicity and phagocytosis. Species-specific differences between murine and human Fcγ receptors represent a major obstacle for translating preclinical findings into clinical outcomes (Smith et al., 2012, Van Damme et al., 2026). The genO-hFcγR model addresses this limitation by replacing murine Fcγ receptor biology with the human receptor repertoire, allowing therapeutic antibodies to engage effector pathways in a clinically relevant manner (Van Damme et al., 2026). This enables more accurate evaluation of ADCC, ADCP, Fc-engineering strategies, and antibody optimization programs for B-cell depletion. Consequently, the genO-hFcγR model provides a highly complementary tool to humanized immune system models for mechanistic and translational studies of monoclonal antibodies and Fc-engineered therapeutics (Van Damme et al., 2026).

Taken together, the continued expansion of B-cell-depleting therapies requires preclinical systems that accurately reproduce human target biology, immune-cell interactions, and Fc-dependent mechanisms. While conventional mouse models remain valuable for mechanistic studies, next-generation platforms such as genO-BRGSF-HIS, genO-panhCD3 humanized mice, and genO-hFcγR mice offer significantly improved translational relevance. By enabling more predictive assessment of efficacy, safety, and mechanism of action, these models are helping accelerate the development of the next generation of B-cell-targeted therapeutics. Find out more about the applications and advantages of these models by checking our HIS-mice guide, CD3 mice guide and FcγR mice guide.

‍

References

  • Abeles I, Palma C, Meednu N, Payne AS, Looney RJ, Anolik JH. B Cell-Directed Therapy in Autoimmunity. Annu Rev Immunol. 2024;42(1):103-126. doi:10.1146/annurev-immunol-083122-044829
  • Chupp DP, Rivera CE, Zhou Y, et al. A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses. Nat Immunol. 2024;25(8):1489-1506. doi:10.1038/s41590-024-01880-3
  • Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171(3):1581-1587. doi:10.4049/jimmunol.171.3.1581
  • Hu CY, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest. 2007;117(12):3857-3867. doi:10.1172/JCI32405
  • Kessel A, Rosner I, Toubi E. Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol. 2008;34(1):74-79. doi:10.1007/s12016-008-8074-1
  • Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi:10.1038/s41573-020-00092-2
  • Levesque MC, St Clair EW. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol. 2008;121(1):13-23. doi:10.1016/j.jaci.2007.11.030
  • Li Y, Mention JJ, Court N, et al. A novel Flt3-deficient HIS mouse model with selective enhancement of human DC development. Eur J Immunol. 2016;46(5):1291-1299. doi:10.1002/eji.201546132
  • Lopez-Lastra S, Masse-Ranson G, Fiquet O, et al. A functional DC cross talk promotes human ILC homeostasis in humanized mice. Blood Adv. 2017;1(10):601-614. Published 2017 Apr 6. doi:10.1182/bloodadvances.2017004358
  • Lykken JM, Horikawa M, Minard-Colin V, et al. Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. Blood. 2016;127(15):1886-1895. doi:10.1182/blood-2015-11-681130
  • Martin GH, Gonon A, Martin-Jeantet P, et al. Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model. Front Immunol. 2024;15:1357716. Published 2024 Feb 7. doi:10.3389/fimmu.2024.1357716
  • Martin GH, Hedir S, Creusat F, et al. Tumor-dependent myeloid and lymphoid cell recruitment in genO-BRGSF-HIS mice: a novel tool for evaluating immunotherapies. Front Immunol. 2025;16:1624724. Published 2025 Sep 17. doi:10.3389/fimmu.2025.1624724
  • Majocchi S, Lloveras P, Nouveau L, et al. NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control. Cancer Immunol Res. 2025;13(3):365-383. doi:10.1158/2326-6066.CIR-24-0298
  • Perico L, Casiraghi F, Sônego F, et al. Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases. Front Immunol. 2024;15:1335998. Published 2024 Feb 26. doi:10.3389/fimmu.2024.1335998
  • Semple KM, Gonzaléz CM, Zarr M, Austin JR, Patel V, Howard KE. Evaluation of the Ability of Immune Humanized Mice to Demonstrate CD20-Specific Cytotoxicity Induced by Ofatumumab. Clin Transl Sci. 2019;12(3):283-290. doi:10.1111/cts.12613
  • Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci U S A. 2012;109(16):6181-6186. doi:10.1073/pnas.1203954109
  • Sun Y, Yuan Y, Zhang B, Zhang X. CARs: a new approach for the treatment of autoimmune diseases. Sci China Life Sci. 2023;66(4):711-728. doi:10.1007/s11427-022-2212-5
  • Tedder, T.F., Baras, A. & Xiu, Y. Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immun 28, 351–364 (2006). https://doi.org/10.1007/s00281-006-0057-9
  • Torres JB, Roodselaar J, Sealey M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022;13:814064. Published 2022 Jul 28. doi:10.3389/fimmu.2022.814064
  • Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199(12):1659-1669. doi:10.1084/jem.20040119
  • Van Damme KFA, Sichien D, Van der Borght K, et al. Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling. Sci Immunol. 2026;11(115):eady7328. doi:10.1126/sciimmunol.ady7328

Related products

Catalogue product

genO-BRGSF-HIS

genO‑BRGSF‑HIS mice possess the most functional reconstituted human immune system currently on the market and are highly relevant for translational research.

genO-panhCD3

genO‑panhCD3 (humanized ε, δ and γ chains - hCD3edg) immunocompetent mice enable the in vivo efficacy and safety assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

‍

genO-hFcγR

Preclinical humanized Fc-gamma receptor (genO‑hFcγR) model enabling the in vivo assessment of Fc receptor-targeted therapies.

‍

Customized product

No items found.
Other scientific insights
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe